Chord-TAV strain distribution was up to 42% lower than for fabricated chordless valves. Chord-TAVs exhibited satisfactory hydrodynamics for size 23 valves. Initial AWT testing data indicated that strain reduction continues following cyclic loading (Fig.1) .
in select populations. This sample cohort validates the feasibility of a primary operative strategy in elderly patients with AS and acceptable risk profiles.
TCT-759
Correlates Weill-Cornell Medical College and Methodist DeBakey Heart Center, Houston, TX Background: Low-Flow Low-Gradient (LF-LG) or "Paradoxical Aortic Stenosis" is a rarely encountered clinical entity with limited data on clinical outcomes after surgical (SAVR) or trans-catheter aortic valve (TAVI) replacement. We conducted a meta-analysis of all the studies comparing all-cause mortality after aortic valve replacement in LF-LG AS in comparison to medical therapy alone. Methods: A thorough PubMed (time-unlimited till 06/01/2013) search revealed 5 studies comparing TAVI/SAVR outcomes in LF-LG aortic stenosis (mean gradient <40mmHg; stroke volume index <35ml/m2). Primary clinical endpoint was all-cause mortality at 2 year follow-up. Odds ratio (OR) and confidence interval (CI) were estimated using the random effects model. Results: A total of 607 patients (SAVR/TAVI 263; medical therapy 344) were included in the analysis. Baseline characteristics of these patients in valve replacement and medical therapy arms were comparable. At 2-year follow-up, SAVR/TAVI was associated with lower all-cause mortality (24.3% vs. 55.8%; OR 0.23; 95% CI 0.15 -0.36). This corresponds to an absolute risk reduction of 31.5% and a Number Needed to Treat 3.55 to save one life. Re-operation for bleeding, n (%) 3 (2.5%)
30-day or in-hospital mortality, n (%) 9 (7.6%) Background: Bleeding after TAVI still remains a frequent and potentially serious complication. A common cause of bleeding in this population might be represented by excessive intraprocedural anticoagulation with heparin. Adjusted heparin dose administration using baseline ACT guidance may reduce the risk of overdosing in this frail population. The aim of our study is to evaluate the impact of the Activated Clotting Time (ACT)-guided heparin administration on bleeding occurrence during trans-femoral (TF) Transcatheter Aortic Valve Implantation (TAVI). Methods: Among 362 patients undergoing TF-TAVI, heparin was administered according to two strategies: baseline ACT (ACT-guided, n¼174) or patient's body weight (non ACT-guided n¼188 patients). The primary study objective was 30-day major bleeding occurrence as defined by the Valve Academic Research Consortium (VARC) criteria. Secondary objectives were any life-threatening and minor bleeding, vascular complications, acute kidney failure, myocardial infarction, stroke, all-cause and cardiovascular mortality at 30 days according to VARC. Results: Bleeding occurred in 167 (46.1%) patients; of these 76 (21.0%) had major bleeding. Of note, the ACT-guided group had a significant lower occurrence of major (7.5% vs. 33.5%, p <0.001), life-threatening (12.1% vs. 20.2%, p¼0.04) and any bleeding (25.9% vs.64.9%, p <0.001). Conversely, no differences were noted in the other secondary study objectives. Importantly, irrespective of the time the procedure was performed (experience phase) and of the operator preference in heparin administration, the ACT-guided strategy was associated with a significant lower occurrence of major bleeding at 30 days. Moreover, after multivariate adjustment for potential confounders ACT-guided propensity, the absence of ACT guidance was an independent predictor of major bleeding at 30 days [OR 6.4, ), p< 0.001].
Conclusions: In our experience, ACT guidance in TF-TAVI was correlated with a significant lower occurrence of major, life-threatening and any bleeding. This strategy might be an useful tool in reducing bleeding in this high-risk population.
TCT-762
Is a high pacing rate post TAVI associated with appropriate pacemaker utilisation? A real-world multi-centre retrospective analysis of pacemaker utilisation in patients paced following TAVI Background: Transcatheter aortic valve implantation (TAVI) is an increasingly common procedure in elderly and multimorbid patients with aortic stenosis. A preprocedural risk evaluation scheme beyond current surgical risk scores has not been widely implemented. Methods: We developed a risk algorithm for 1-year mortality in two cohorts consisting of 845 patients undergoing routine transapical or transfemoral TAVI procedures by commercially available devices, mean age 80.9AE6.5, 51% women. Clinically available variables and surgical risk scores were determined at baseline. Multivariable Cox regression related clinical data to mortality (n¼207 deaths). Results: Age, sex, body mass index, estimated glomerular filtration rate, hemoglobin, pulmonary hypertension, and mean transvalvular gradient and left ventricular ejection fraction at baseline were most strongly associated with mortality (C-statistic 0.66, 95% confidence interval [CI] 0.61 to 0.70, calibration Chi 2 statistic¼ 6.51; p¼0.69). B-type natriuretic peptide and troponin I were significantly related to outcome after multivariable-adjustment, but did not improve the C-statistic. Frailty increased the Cstatistic to 0.71 (95% CI 0.65 to 0.76). Conclusions: We present a specific risk evaluation tool derived and validated in routine TAVI cohorts that predicts 1-year mortality better than the conventional scoring systems. Biomarkers only marginally improved risk prediction. Our risk algorithm may help to guide decision-making when TAVI is planned. 
